medigraphic.com
ISSN 2007-8013 (Print)
Órgano oficial de la Universidad Autónoma de Sinaloa

2022, Number 4

<< Back Next >>

Rev Med UAS 2022; 12 (4)

Incidence of gastroesophageal reflux disease after helicobacter pylori eradication in Mexico. Quasi-experimental study

Sánchez-Cuén JA, Rosas-López PF, Gámez-Valenzuela J, Bernal-Magaña G, Garay-Núñez JR, Irineo-Cabrales AB

Language: Spanish
References: 30
Page: 280-288
PDF size: 220.69 Kb.


ABSTRACT

Objective. It was to determine the incidence of Gastroesophageal Reflux Disease after the successful eradication of Helicobacter pylori infection in a specialty hospital. Materials and methods. A quasi-experimental study was carried out. The population studied were subjects with no history of gastroesophageal reflux, an upper gastrointestinal endoscopy was performed, confirming Helicobacter pylori infection, and they received successful standard triple therapy. Consultation follow-up to identify symptoms of gastroesophageal reflux and upper gastrointestinal endoscopy one year later. Statistical design with Fisher and McNemar exact test. Results. We reviewed 58 subjects, 37 (63, 8%) women and 21 (36, 2%) men. mean age was 57, 1 years (SD 13, 2). The most frequent indication for endoscopy was dyspepsia in 38 (65, 5%) subjects. The incidence of reflux disease was in 20 (34, 5%) subjects at one year of follow-up. Erosive and non-erosive reflux disease was in 10 (17, 2%) subjects in both. Conclusions. The incidence of reflux disease after Helicobacter pylori eradication with standard triple therapy as high as other countries in the world.


REFERENCES

  1. Scida S, Russo M, Miraglia C, Leandro G,Franzoni L, Meschi T, et al. Relationship betweenHelicobacter pylori infection andGERD. Acta Biomed 2018; 17; 89(8-S):40-43.

  2. Vakil N, van Zanten SV, Kahrilas P, Dent J,Jones R. The Montreal definition and classificationof gastroesophageal reflux disease:a global evidence based consensus. Am JGastroenterol 2006; 101: 1900-20.

  3. El-Serag HB, Sweet S, Winchester CC, DentJ. Update on the epidemiology of gastroesophagealreflux disease: a systematic review.Gut 2014; 63(6):871-80.

  4. Sukano K. Vonoprazan fumarate, a novelpotassium –competitive acid blocker, in themanagement of gastroesophageal reflux disease:safety and clinical evidence to date.Therap Adv Gastroenterol 2018 9;11:1756283X17745776.

  5. Herrera EJL, Monreal RR, García CD, GonzálezMEI, Borjas AOD, Maldonado GHJ,et al. Prevalence of Barrett's esophagus: Anobservational study from a gastroenterologyclinic. Rev Gastroenterol Mex 2017;82(4):296-300.

  6. Gyawali CP, Kahrilas PJ, Savarino E, ZerbibF, Mion F, Smout AJPM, et al. Modern diagnosisof GERD: the Lyon Consensus Gut2018; 67(7):1351-1362.

  7. Gislason T, Janson C, Vermeire P, PlaschkeP, Björnsson E, Gislason D ,et al. Respiratorysymptoms and nocturnal gastro-esophagealreflux: A population based study ofyoung adults in three European countries.Chest 2002; 121:158-63.

  8. Akyüz F, Mutluay Soyer Ö. Which diseasesare risk factors for developing gastroesophagealreflux disease? Turk J Gastroenterol2017; 28(Suppl 1):S44-S47.

  9. Akyüz F, Mutluay Ö. How is gastroesophagealreflux disease classified? Turk J Gastroenterol2017; 28 (Suppl 1): S10-S11.

  10. Vaishnav B, Bamanikar A, Maske P, ReddyA, Dasgupta S. Gastroesophageal RefluxDisease and its Association with Body MassIndex: Clinical and Endoscopic Study. J ClinDiagn Res 2017; 11(4):OC01-OC04.

  11. Richter JE, Rubenstein JH. Presentation andEpidemiology of Gastroesophageal RefluxDisease. Gastroenterol 2018; 154(2): 267–276.

  12. Huerta F. Enfermedad por reflujo no erosiva.Rev Gastroenterol Mex 2006; 71(Supl. 1):60-61.

  13. Gasiorowska A. The role of pH in symptomaticrelief and effective treatment of gastroesophagealreflux disease. Prz Gastroenterol2017; 12(4):244-249.

  14. Graham DY. History of Helicobacter pylori,duodenal ulcer, gastric ulcer and gastric cancer.World J Gastroenterol 2014;20(18):5191-204.

  15. Hooi JKY, Lai WY, Ng WK, Suen MMY, UnderwoodFE, Tanyingoh D, et al. GlobalPrevalence of Helicobacter pylori Infection:Systematic Review and Meta-Analysis. Gastroenterol2017; 153(2):420-429.

  16. Alarid-Escudero F, Enns EA, MacLehoseRF, Parsonnet J, Torres J, Kuntz KM. Forceof infection of Helicobacter pylori in Mexico:evidence from a national survey using a hierarchicalBayesian model. Epidemiol Infect2018; 146(8):961-969.

  17. Bae SE, Choi KD, Choe J. The effect of eradicationof Helicobacter pylori on gastric cancerprevention in healthy asymptomatic populations.Helicobacter 2018.

  18. Doorakkers E, Lagergren J, Engstrand L,Brusselaers N. Helicobacter pylori eradicationtreatment and the risk of gastric adenocarcinomain a Western population. Gut2018 1; 67 2092-6. (12).

  19. Yucel O. Interactions between Helicobacterpylori and gastroesophageal reflux disease.Esophagus 2019 ;16(1):52-62.

  20. Mungan Z, Pınarbaşı Şimşek B. Gastroesophagealreflux disease and the relationshipwith Helicobacter pylori. Turk J Gastroenterol2017; 28 (Suppl 1): S61-S67.

  21. Ghoshal UC, Chourasia D. GastroesophagealReflux Disease and Helicobacter pylori:What May Be the Relationship?. J NeurogastroenterolMotil 2010; 16(3):243-50.

  22. Jie W, Qinghong X, Zhitao Ch. Associationof Helicobacter pylori infection with gastroesophagealreflux disease. J Int Med Res2019; 47(2): 748–753.

  23. Nakajima S, Hattori T. Active and inactivegastroesophageal reflux diseases related toHelicobacter pylori therapy. Helicobacter2003; 8(4):279-93.

  24. Correa P, Piazuelo MB. The gastric precancerouscascade. J Dig Dis 2012;13:2-9.

  25. Peetsalu A, Kirsimägi U, Peetsalu M. Giantpeptic ulcer hemorrhages: Epidemiology,treatment, and outcome in the teaching hospitalof Tartu. Medicina (Kaunas) 2011;47(1):19-24.

  26. Fallone CA, Barkun AN, Friedman G, MayrandS, Loo V, Beech R, et al. Is Helicobacterpylori eradication associated with gastroesophagealreflux disease? Am J Gastroenterol2000; 95(4):914-20.

  27. Abdo-Francis JM, Uscanga-Domínguez LF,Sobrino-Cossio S, Rivera- Ramos JF,Huerta-Higa F, Tamayo de la Cuesta JL, etal. Tercer consenso mexicano de Helicobacterpylori. Rev Gastroenterol Mex 2007;72(3):321-38.

  28. Hamada H, Haruma K, Mihara M, KamadaT, Yoshihara M, Sumii K, et al. High incidenceof reflux oesophagitis after eradicationtherapy for Helicobacter pylori: impactsof hiatal hernia and corpus gastritis. AlimentPharmacol Ther 2000; 14(6):729-35.

  29. Inoue H, Imoto I, Taguchi Y, Kuroda M,Nakamura M, Horiki N, et al. Reflux esophagitisafter eradication of Helicobacter pylori isassociated with the degree of hiatal hernia.Scand J Gastroenterol 2004; 39(11):1061-5.

  30. Pasechnikov VD, Chotchaeva AR, PasechnikovDV. [Effect of HP eradication on thedevelopment of gastroesophageal reflux disease:results of the prospective study]. EkspKlin Gastroenterol 2011 ;( 3):105-10.




2020     |     www.medigraphic.com